The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation

NCT05220410 ↗

Phase 2 Completed 20 enrolled Sheppard Pratt Health System COMPASS Pathways · collab

NaSingle-groupOpen-labelTreatment

Summary

This study aims to explore the safety and tolerability of a single dose of psilocybin (25mg) administered under supportive conditions to adult participants with TRD and chronic suicidal ideation

Timeline

Start: 2022-03-28
Primary completion: 2025-05-12
Completion: 2025-05-12

Publications

van der Vaart A, LaPratt J, Swartz K, Shoultz A, Lauterbach M, Suppes T, Sackeim HA, Aaronson ST. Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal Ideation: An Open-Label Trial. J Clin Psychiatry. 2026 May 13;87(2):26m16338. doi: 10.4088/JCP.26m16338.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Psilocybin	Other / unclassified	25 mg	—

Indications

No indication recorded.